CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.05.14	Cellectis Plant Sciences Reports Generation of High Oleic Soybean in Journal of Plant Biotechnology (Businesswire)
19.05.14	TAL-effector Nuclease: The USPTO Issues a Fourth Patent Licensed to Cellectis (Businesswire)
11.04.14	Cellectis: 2013 financial results (Businesswire)
31.03.14	Cellectis Announces the Closing of €20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors (Businesswire)
25.03.14	Cellectis Receives €20.5 M in Commitments in Private Placement from U.S. Biotechnology Specialist Institutional Investors (Businesswire)
17.02.14	Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors (Businesswire)
05.02.14	US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases (Businesswire)
04.02.14	Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models (Businesswire)
30.01.14	Precision BioSciences and Cellectis SA Announce Cross-License and Settlement Agreement for Gene Editing Technology (Businesswire)
30.01.14	Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing (Businesswire)
17.01.14	Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays (Businesswire)
09.01.14	Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program (Businesswire)
07.01.14	Cellectis Reorganizes Its Tools and Services Business Line, in Partnership with Caisse Des Dépôts, by Contributing Ectycell’s Shares to Cellectis Bioresearch (Businesswire)
05.12.13	Cellectis announces an acceleration of its strategic refocusing on therapeutics and agrobusiness (Businesswire)
26.09.13	Cellectis announces first-half 2013 financial results (Businesswire)
23.09.13	Cellectis Bioresearch Launches Compact TALENTM the Next Generation of TAL Effector Nucleases (Businesswire)
08.07.13	Scéil(TM) : A New Offering for the General Public to Turn Adult Cells into Stem Cells and Store Them (Businesswire)
04.07.13	Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia (Businesswire)
18.12.12	Cellectis: An Innovative Anti-cancer Approach (Businesswire)
12.11.12	2012 Nobel laureate in medicine Shinya Yamanaka reaffirms commitment to CiRA-Cellectis partnership (Businesswire)
29.10.12	Cellectis Presents Breakthrough in Fight against Cancer at ESGCT Congress (Businesswire)
25.10.12	Cellectis extends its TAL technology intellectual property portfolio through the acquisition of two exclusive licenses from Iowa State University (Businesswire)
23.10.12	Cellectis bioresearch Inc. wins a $6.9 million contract with The National Institutes of Health on iPS cells (Businesswire)
16.10.12	The National Institutes of Health awarded a contract to Cellectis bioresearch Inc. (Businesswire)
08.10.12	Cellectis: the Award of Nobel Prize in Medicine to Professor Yamanaka Confirms the Relevance of the Group's Stem Cell Strategy (Businesswire)
04.10.12	Medicago and Cellectis Successfully Achieve First Step in Research Collaboration (Businesswire)
02.10.12	Cellectis Publishes Results Paving the Way for New Therapeutic Approaches against Cancer and Genetic Diseases (Businesswire)
24.09.12	Cellectis stem cells today announces the release of a new and improved user friendly format of stem cell derived cardiomyocytes (Businesswire)
20.09.12	Cellectis: 2012 first-half earnings (Businesswire)
10.09.12	Cellectis: A step towards a new therapy for AIDS (Businesswire)
25.06.12	Combined general meeting for Cellectis shareholders on June 22nd, 2012 (Businesswire)
21.05.12	Cellectis stem cells today proudly announces the launch of the world’s very first human iPS cell-derived hepatocyte product (Businesswire)
02.04.12	Appointment of Mathieu Simon, MD, to the Position of Senior Vice-President of Cellectis Group (Businesswire)
13.02.12	Cellectis announces the redemption of the bonds redeemable into shares subscribed by the FSI and Pierre Bastid for a total of €50 million (Businesswire)
31.01.12	Cellectis Plant Sciences Announces the Signature of a Strategic Partnership with SESVanderHave in Sugar Beet (Businesswire)
30.01.12	Changes in the Group's Scientific Division and Appointment of the CEO of Cellectis Plant Sciences (Businesswire)
16.01.12	Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology (Businesswire)
09.01.12	Cellectis Launches a Partnership with Total for Exploratory Research into Microalgae-Based Substitutes for Oil Products (Businesswire)
03.01.12	Cellectis plant sciences and Bayer CropScience strengthen genome engineering partnership (Businesswire)
08.12.11	Starbucks Enters Five New Cities Across Mainland China (Businesswire)
08.12.11	Cellectis bioresearch and Syngene Announce Partnership on the Development of Customized Cell Lines (Businesswire)
05.12.11	Cellectis Signs a License Agreement Under Patents Covering Uses of Homologous Recombination With Global Pharmaceutical Company (Businesswire)
07.11.11	Cellectis Announces the Final Completion of the Acquisition of Cellartis and €50 Million Financing Round Reserved for the FSI and Mr. Pierre Bastid (Businesswire)
14.10.09	Cellectis Launches a Capital Increase without Preferential Subscription Rights Through a Private Placement to Qualified Investors of Approximately € 20 Million (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten